Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma.

ABSTRACT:

Background

Treatment of renal cancer has significantly improved with the arrival to the clinic of kinase inhibitors and immunotherapies. However, the disease is still incurable in advanced stages. The fact that several approved inhibitors for kidney cancer target receptor tyrosine kinases (RTKs) suggests that these proteins play a critical role in the pathophysiology of the disease. Based on these precedents, we decided to explore whether RTKs other than those targeted by approved drugs, contribute to the development of kidney cancer.

Methods

The activation status of 49 RTKs in 44 paired samples of normal and tumor kidney tissue was explored using antibody arrays, with validation by western blotting. Genetic and pharmacologic approaches were followed to study the biological

SUBMITTER: Garcia-Alonso S 

PROVIDER: S-EPMC8365933 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature